Ticker
ACER

Price
1.52
Stock movement up
+0.01 (0.66%)
Company name
Acer Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
23.71M
Ent value
44.48M
Price/Sales
65.87
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-40.63%
3 year return
-12.38%
5 year return
-31.17%
10 year return
-37.45%
Last updated: 2022-08-25

DIVIDENDS

ACER does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales65.87
Price to Book-
EV to Sales123.56

FINANCIALS

Per share

Loading...
Per share data
Current share count15.60M
EPS (TTM)-0.76
FCF per share (TTM)-0.44

Income statement

Loading...
Income statement data
Revenue (TTM)360.00K
Gross profit (TTM)0.00
Operating income (TTM)-11.49M
Net income (TTM)-10.92M
EPS (TTM)-0.76
EPS (1y forward)-0.29

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-3190.72%
Profit margin (TTM)-3033.59%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash20.80M
Net receivables0.00
Total current assets23.35M
Goodwill7.65M
Intangible assets0.00
Property, plant and equipment0.00
Total assets31.47M
Accounts payable2.02M
Short/Current long term debt13.33M
Total current liabilities27.58M
Total liabilities41.57M
Shareholder's equity-10.10M
Net tangible assets-10.10M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-6.15M
Capital expenditures (TTM)78.55K
Free cash flow (TTM)-6.23M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-34.70%
Return on Invested Capital108.11%
Cash Return on Invested Capital61.69%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.52
Daily high1.55
Daily low1.51
Daily Volume146K
All-time high414221.04
1y analyst estimate9.67
Beta1.40
EPS (TTM)-0.76
Dividend per share-
Ex-div date-
Next earnings date17 Nov 2022

Downside potential

Loading...
Downside potential data
ACERS&P500
Current price drop from All-time high-100.00%-13.41%
Highest price drop-100.00%-56.47%
Date of highest drop22 Aug 20229 Mar 2009
Avg drop from high-98.79%-11.38%
Avg time to new high408 days12 days
Max time to new high4444 days1805 days
COMPANY DETAILS
ACER (Acer Therapeutics Inc) company logo
Marketcap
23.71M
Marketcap category
Small-cap
Description
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Employees
39
Investor relations
-
SEC filings
CEO
Christopher Schelling
Country
USA
City
Newton
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.
September 15, 2022
Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.
September 13, 2022
NEWTON, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious,...
August 23, 2022
NEWTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious,...
August 15, 2022
Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approvalGENEVA, Switzerland and NEWTON, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTIC...
August 12, 2022
Phase 2a trial initiation planned for the first half of 2023 subject to IND clearance and available capitalNEWTON, Mass. and GENEVA, Switzerland, July 28, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics In...
July 28, 2022
Prescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023NEWTON, Mass. and GENEVA, July 28, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and its colla...
July 28, 2022
ACER, BAK, and CJPRY have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2022.
July 28, 2022
Acer has notified the FDA in the resubmission that the third-party contract packaging manufacturer is ready for inspectionNEWTON, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasda...
July 18, 2022
ACER, HMN, and STT have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2022.
July 15, 2022
Next page